 |
|
|
| |
HIV-1 RNA Blips, Low-Level Viral Replication, and Mean CD4+/CD8+ Ratio During Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies Up to 152 Weeks of Therapy
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Christine Latham,1 Louise Garside,2 Sri Byrapuneni,3 Conor Smith,4 Marty St. Clair,1 Veerle Van Eygen,5 Sandy Griffith,1 Ronald D'Amico,1 Jan van Lunzen,6 Jean van Wyk,6 William Spreen1
1ViiV Healthcare, Durham, NC, USA; 2GSK, Brentford, UK; 3Parexel International, Research Triangle Park, NC, USA; 4Parexel International, Sheffield, UK; 5Janssen Research and Development, Beerse, Belgium;
6ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
